Clinical research is necessary for investigating the relationship between the expression of CDK4 and clinical characteristics, such as the HCC stage and prognostic value, as it may help identify novel markers for tracking the evolution of the tumor, advancing medication development, and enhancing treatment methods. This evidence concerns the gene CDK4 and hepatocellular carcinoma.